Home

Novartis Bioventures Ltd

CIK 1297709 · last filed 2020-06-22

Novartis Bioventures Ltd is a corporate insider who has filed 44 SEC Form 4 insider transactions across 11 companies since 2011. The most recent filing shows the insider sold $16.5M of GRTX on Jun 22, 2020. Across all open-market trades the lifetime net is −$22.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $32.8M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$32.77M

Companies

11

Total Filings

44

Lifetime Open-Market Net

-$21.96M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
GRTX 10%+ Owner 35,061 $17.60 $617.1K -$11.18M 4 2020-06-22
BCYC 10%+ Owner 1,769,641 $3.94 $6.97M $4.72M 1 2019-05-30
Whitehawk Therapeutics, Inc. (ARPO) Delisted 10%+ Owner 279,234 $33.00 $9.21M -$2.89M 6 2019-04-29
Rein Therapeutics, Inc. (ALRN) Delisted 10%+ Owner 105,000 $2.11 $221.6K -$1.69M 9 2019-04-02
ALT 10%+ Owner 8,345,145 $2.99 $24.95M $0 8 2018-09-14
Spyre Therapeutics, Inc. (AGLE) Delisted 10%+ Owner 2,175,314 $12.01 $26.13M -$2.74M 3 2018-05-14
Ra Pharmaceuticals, Inc. (RARX) Delisted 10%+ Owner 2,254,677 — — -$12.06M 7 2017-06-20
Eledon Pharmaceuticals, Inc. (TKAI) Delisted 10%+ Owner 499,273 — — -$133.7K 2 2015-07-17
AKBA 10%+ Owner 182,590 $1.27 $231.9K $3.10M 1 2014-03-27
Eiger BioPharmaceuticals, Inc. (CLDN) Delisted 10%+ Owner 103,448 — — $1.30M 1 2014-02-06
Adhera Therapeutics, Inc. (MRNAD) Delisted 10%+ Owner 2,560,565 — — -$383.4K 1 2011-01-27

Recent Filings

44 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-06-22 GRTX Sell (S) −2,004,424 -$16.54M EDGAR
2020-06-17 GRTX Sell (S) −38,772 -$357.2K EDGAR
2020-06-04 GRTX Sell (S) −29,930 -$289.7K EDGAR
2019-11-12 GRTX Mixed +7,086,134 $6.00M EDGAR
2019-05-30 BCYC Mixed +3,539,282 $4.72M EDGAR
2019-04-29 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −1,403,600 -$1.45M EDGAR
2019-04-24 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −102,114 -$104.3K EDGAR
2019-04-15 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −234,280 -$245.4K EDGAR
2019-04-10 Whitehawk Therapeutics, Inc. (ARPO) Delisted Sell (S) −401,492 -$428.5K EDGAR
2019-04-02 Rein Therapeutics, Inc. (ALRN) Delisted Sell (S) −254,300 -$472.5K EDGAR
Showing 1–10 of 44
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.